Clinical Trials, Phase IV as Topic
"Clinical Trials, Phase IV as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
MeSH Number(s)
E05.318.760.535.230
E05.337.250.230
E05.337.800.200
N05.715.360.775.235.230
N06.850.520.450.535.230
Concept/Terms
Drug Evaluation, FDA Phase IV as Topic- Drug Evaluation, FDA Phase IV as Topic
- Evaluation Studies, FDA Phase 4 as Topic
- Drug Evaluation, FDA Phase 4 as Topic
- Evaluation Studies, FDA Phase IV as Topic
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase IV as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase IV as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase IV as Topic" by people in Harvard Catalyst Profiles by year, and whether "Clinical Trials, Phase IV as Topic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 3 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Clinical Trials, Phase IV as Topic" by people in Profiles.
-
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023 11 15; 67(11):e0073723.
-
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022 Dec; 68:104143.
-
Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. Med Mycol. 2021 Jul 06; 59(7):712-719.
-
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegener Dis Manag. 2021 04; 11(2):99-111.
-
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor a. Clin Cancer Res. 2020 06 15; 26(12):2986-2996.
-
A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. J Clin Epidemiol. 2019 10; 114:60-71.
-
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. Leuk Lymphoma. 2019 10; 60(10):2384-2393.
-
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017 10; 15(10):1913-1922.
-
Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. Circulation. 2017 May 23; 135(21):2062-2072.
-
Particle Therapy at the "Tipping Point": An Introduction to the Red Journal's Special Edition. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):1-3.